z-logo
Premium
Chirality Controls Reaction‐Diffusion of Nanoparticles for Inhibiting Cancer Cells
Author(s) -
Du Xuewen,
Zhou Jie,
Wang Jiaqing,
Zhou Rong,
Xu Bing
Publication year - 2017
Publication title -
chemnanomat
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 32
ISSN - 2199-692X
DOI - 10.1002/cnma.201600258
Subject(s) - cancer cell , nanomedicine , chemistry , cancer , nanoparticle , cisplatin , chirality (physics) , biochemistry , biophysics , nanotechnology , materials science , biology , chiral symmetry breaking , physics , genetics , chemotherapy , quantum mechanics , quark , nambu–jona lasinio model
Reaction‐diffusion (RD) is the most important inherent feature of living organisms, but it has yet to be used for developing biofunctional nanoparticles (NPs). Here we show the use of chirality to control the RD of NPs for selective inhibition of cancer cells. We observe that l ‐phosphotyrosine ( l ‐pY)‐decorated NPs (NP@ l ‐pYs) are innocuous to cells, but d ‐pY‐decorated ones (NP@ d ‐pYs) selectively inhibit cancer cells. Our study shows that phosphatases, present in the culture and overexpressed on the cancer cells, dephosphorylate NP@ l ‐pYs much faster than NP@ d ‐pYs. Such a rate difference allows the NP@ d ‐pYs to be mainly dephosphorylated on cell surface, and thus adhere selectively on the cancer cells, resulting in poly(ADP‐ribose)polymerase (PARP)‐hyperactivation‐mediated cell death. Without phosphate groups or with premature dephosphorylation before reaching cancer cells (as in the case of NP@ l ‐pYs), the NPs are innocuous to cells. Moreover, NP@ d ‐pYs exhibit even more potent activity than cisplatin for inhibiting platinum‐resistant ovarian cancer cells (e.g., A2780‐cis). As the first example of chirality controlling a RD process of NPs for inhibiting cancer cells, this work illustrates a fundamentally new way to develop nanomedicine based on RD processes and nanoparticles.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here